Clinical Trial

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an early-phase clinical study investigating a new combination treatment, Ris-Rez given with ivonescimab for adults with advanced solid cancers. The study aims to determine: * What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects? * How does the body handle the drug(s)? * What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?
Trial Details
NCT Number NCT07602855
Lead Sponsor GlaxoSmithKline
Conditions Solid Tumors
Enrollment 184 participants
Start Date 2026-09-08
Primary Completion 2029-07-05 (estimated)
Study Completion 2030-01-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-22